T. Hobday

发表

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Zachary L. Skidmore, O. Griffith, M. Ellis, 2017, Clinical Cancer Research.

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.

E. D. de Vries, E. Van Cutsem, James C Yao, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

J. Berlin, E. Mittra, E. Van Cutsem, 2017, The New England journal of medicine.

Germline genetic variants in ABCB1, ABCC1, and ALDH1A1 and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

G. Hortobagyi, Song Liu, C. Isaacs, 2013, The Pharmacogenomics Journal.

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

A. Carrato, E. Raymond, T. Hobday, 2011, Cancer and Metastasis Reviews.

A single-center experience with inflammatory breast cancer, 1985-2003.

J. Donohue, A. Degnim, D. Farley, 2006, Archives of surgery.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Anastasia Ivanova, Charles M Perou, Katherine A Hoadley, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group ( NCCTG ) trials

E. Perez, A. Dueck, D. Northfelt, 2011 .

Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

E. Perez, A. Dueck, D. Northfelt, 2011, Clinical Cancer Research.

Carcinoid heart disease.

P. Pellikka, M. Abel, T. Hobday, 2007, Progress in cardiovascular diseases.

Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival.

G. Hortobagyi, A. Hutson, C. Isaacs, 2020, Journal of the National Cancer Institute.

The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors

C. Lohse, T. Smyrk, T. Hobday, 2018, The American journal of surgical pathology.

Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.

R. Goldberg, T. Hobday, 2002, Clinical colorectal cancer.

Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy

T. Hobday, A. Jatoi, G. Croghan, 2008, Therapeutics and clinical risk management.

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

S. Severi, D. Metz, J. Berlin, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Regional Differences in Breast Cancer Biomarkers in American Indian and Alaska Native Women

R. Vierkant, D. Visscher, T. Hobday, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis

T. Hobday, T. Halfdanarson, S. Cleary, 2022, The oncologist.

Imatinib mesylate-induced interstitial pneumonitis.

J. Jett, T. Hobday, Cynthia X. Ma, 2003, Mayo Clinic proceedings.

Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors

B. Costello, Mojun Zhu, C. Erlichman, 2021, Pancreas.

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

Helen X. Chen, H. Lenz, M. Moore, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, JNCI cancer spectrum.

The effect of metformin vs placebo on sex hormones in CCTG MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2020, Journal of the National Cancer Institute.

NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE.

R. Baum, E. Krenning, T. Hobday, 2016 .

First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.

E. Krenning, T. Hobday, P. Ruszniewski, 2018 .

Translational correlates, including outcome for patients with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC)

M. Aubry, M. Aubry, W. Lingle, 2007 .

177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors : Results of the Phase III NETTER-1 Trial

E. Mittra, E. Krenning, T. Hobday, 2016 .

N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy

E. Perez, M. Goetz, T. Hobday, 2008 .

The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003.

E. Winer, A. Wolff, N. Lin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy

C. Loprinzi, T. Hobday, K. Anderson, 2014, Supportive Care in Cancer.

MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

R. Lloyd, M. Mahoney, R. Donehower, 2007 .

E. Krenning, T. Hobday, P. Ruszniewski, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane.

E. Perez, K. Rowland, D. Northfelt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.

James C Yao, T. Hobday, C. Lombard-Bohas, 2015 .

Supplement use during an intergroup clinical trial for breast cancer (S0221)

G. Hortobagyi, C. Isaacs, J. Unger, 2013, Breast Cancer Research and Treatment.

S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.

T. Hobday, T. Halfdanarson, A. Kendi, 2020, The oncologist.

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2022, JAMA.

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.

E. Van Cutsem, T. Hobday, C. Lombard-Bohas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

R. Lloyd, M. Mahoney, R. Donehower, 2005 .

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.

C. Erlichman, T. Hobday, J. Rubin, 2005, Mayo Clinic proceedings.

Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options.

T. Bekaii-Saab, J. Ashman, T. Hobday, 2020, Clinical colorectal cancer.

6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial

E. Mittra, T. Hobday, P. Ruszniewski, 2015 .

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, G. Hortobagyi, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, G. Hortobagyi, 2017, Journal of the National Cancer Institute.

Assessment of Discrimination, Bias, and Inclusion in a United States Hematology and Oncology Fellowship Program

T. Hobday, A. Kumbamu, S. Hayes, 2021, JAMA network open.

The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, Journal of the National Cancer Institute.

A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer

E. Perez, A. Jaffe, S. Martino, 2007 .

Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)

E. Mardis, J. Hoog, R. Aft, 2016 .

The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms

T. Hobday, J. Strosberg, T. Halfdanarson, 2019, Neuroendocrinology.

Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy

T. Hobday, T. Halfdanarson, A. Kendi, 2021, The Journal of Nuclear Medicine.

Renal Neuroendocrine Neoplasms: A Single-center Experience.

B. Leibovich, T. Hobday, T. Halfdanarson, 2019, Clinical genitourinary cancer.

Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).

Helen X. Chen, H. Lenz, M. Moore, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose modification for safe treatment of a compound complex heterozygous DPYD variant carrier with 5-fluorouracil.

R. Diasio, T. Hobday, E. Tapper, 2018, JCO precision oncology.

Medical Management of Pancreatic Neuroendocrine Tumors

C. Erlichman, T. Hobday, J. Rubin, 2008, The American Journal of Gastroenterology.

Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).

A. Grothey, J. Bendell, H. Pitot, 2017 .

Medical Treatment of Neuroendocrine Tumors

T. Hobday, 2010 .

Medical Treatment of Advanced Neuroendocrine Tumors

T. Hobday, J. Rubin, 2004 .

Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study

Minetta C. Liu, M. Goetz, T. Haddad, 2022, Breast Cancer Research and Treatment.

Percutaneous Image-Guided Core Needle Biopsy of Neuroendocrine Tumors: How Common Is Intraprocedural Carcinoid Crisis?

T. Atwell, T. Hobday, S. Jang, 2021, Journal of vascular and interventional radiology : JVIR.

NETTER-1 Phase III: Progression-Free Survival, Radiographic Response, and Preliminary Overall Survival Results in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate.

E. Krenning, T. Hobday, P. Ruszniewski, 2016, Clinical advances in hematology & oncology : H&O.

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.

E. D. de Vries, E. Van Cutsem, James C Yao, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

E. Van Cutsem, James C Yao, T. Hobday, 2015, Pancreas.

1132OEVEROLIMUS (EVE) FOR THE TREATMENT OF ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET): FINAL OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO (PBO)-CONTROLLED, MULTICENTER PHASE III TRIAL (RADIANT-3).

E. D. de Vries, E. Van Cutsem, T. Hobday, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of everolimus in patients with advanced low- or intermediate-grade pancreatic neuroendocrine tumors previously treated with chemotherapy: RADIANT-3 subgroup analysis.

M. Shah, James C Yao, T. Hobday, 2013 .

Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.

T. Hobday, D. Castellano, T. O'Dorisio, 2013, The oncologist.

Analysis of Progression-Free Survival (PFS) by Prior Chemotherapy Use and Updated Safety in RADIANT-3: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial of Everolimus in Patients with Advanced Low- or Intermediate-Grade Pancreatic Neuroendocrine Tumors (pNET)

James C Yao, T. Hobday, R. Pommier, 2012 .

Updated Survival and Safety Data From RADIANT-3-a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET)

de Elisabeth G. E. Vries, James C Yao, T. Hobday, 2011 .

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Multivariate analysis of progression-free survival from the RADIANT-3 trial.

T. Hobday, J. Capdevila, R. Pommier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3)

M. Shah, James C Yao, T. Hobday, 2011 .

Everolimus for advanced pancreatic neuroendocrine tumors.

E. D. de Vries, E. Van Cutsem, James C Yao, 2011, The New England journal of medicine.

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3).

E. Van Cutsem, T. Hobday, C. Lombard-Bohas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy of colon cancer: a review.

C. Erlichman, T. Hobday, Charles Erlichman, 2002, Clinical colorectal cancer.

Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms

T. Hobday, T. Halfdanarson, J. Gile, 2021, Pancreas.

Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci

Lara E Sucheston-Campbell, G. T. Budd, Abbas A. Rizvi, 2018, Pharmacogenetics and genomics.

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2015, Journal of the National Cancer Institute.

Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, NPJ breast cancer.

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas

R. Lloyd, C. Erlichman, T. Hobday, 2005, Modern Pathology.

Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144.

D. Sargent, R. Goldberg, M. O’connell, 2009, Clinical colorectal cancer.

Risk Factors for Pancreatic Neuroendocrine Tumors: A Clinic-Based Case-Control Study

W. Bamlet, R. McWilliams, T. Hobday, 2014, Pancreas.

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma

M. Goetz, T. Smyrk, N. Foster, 2017, Cancer.

Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

E. Baudin, L. Kvols, P. Rougier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors

R. Lloyd, C. Erlichman, T. Hobday, 2006, Endocrine.

Characterization of the Functional and Growth Properties of Cell Lines Established from Ileal and Rectal Carcinoid Tumors

R. Lloyd, A. Leontovich, T. Hobday, 2007, Endocrine pathology.

Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients

A. Dietz, D. Visscher, T. Hobday, 2018, Clinical Cancer Research.

A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study.

P. Philip, R. Lloyd, M. Mahoney, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

W. Gradishar, G. Sledge, J. Sparano, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.

E. Winer, R. Carlson, C. Reynolds, 2011, The oncologist.

How well do standard prognostic criteria predict oncotype DX (ODX) scores

E. Winer, E. Perez, R. Carlson, 2007 .

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights

T. Hobday, T. Halfdanarson, Akash Sharma, 2020, OncoTargets and therapy.

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

L. Ellis, J. Tepper, E. Van Cutsem, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Neuroendocrine Cancer Metastatic to the Liver: The Role of Ablative Techniques

J. Charboneau, D. Nagorney, F. Que, 2005, CardioVascular and Interventional Radiology.

Treatment of Neuroendocrine Tumor Liver Metastases

T. Hobday, Mark A Lewis, 2012, International journal of hepatology.

Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma

T. Hobday, J. Molina, T. Halfdanarson, 2020, Pancreas.

Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma.

D. Sargent, J. Sloan, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy a nd Q uality-of-Life D ata A re R elated i n a P hase I I Trial o f O ral C hemotherapy i n P reviously U ntreated P atients With M etastatic C olorectal C arcinoma

D. Sargent, J. Sloan, R. Goldberg, 2002 .

Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221)

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, G. Hortobagyi, 2018, Breast Cancer Research.

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

Bingshu E. Chen, T. Whelan, K. Gelmon, 2011, Breast Cancer Research and Treatment.

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

A. D. Van den Abbeele, E. Winer, A. Richardson, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of Factors Associated with Hematology-Oncology Fellow Academic Success and Career Choice

T. Hobday, D. Grill, S. Mann, 2018, Journal of Cancer Education.

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

E. Perez, T. Hobday, B. Laplant, 2016, Clinical breast cancer.

North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.

E. Perez, K. Rowland, A. Dueck, 2012, Clinical breast cancer.

Molecularly targeted therapies for breast cancer.

E. Perez, T. Hobday, 2005, Cancer control : journal of the Moffitt Cancer Center.

Impact of Prior Chemothe rapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors A Subgroup Analysis of the Phase III RADIANT-3 Trial

T. Hobday, C. Lombard-Bohas, M. Shah, 2014 .

CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).

Bingshu E. Chen, T. Whelan, K. Gelmon, 2018 .

Pilot Study Characterizing the Hematology-Oncology Fellow Job Search Process: Tools Used and Identification of Potential New Resources

T. Hobday, T. Halfdanarson, A. Marshall, 2021, Journal of Cancer Education.

Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

A. Dietz, A. Degnim, A. Dueck, 2019, Clinical Cancer Research.

Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)

G. Hortobagyi, Song Liu, C. Isaacs, 2011, Breast Cancer Research and Treatment.

Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs).

T. Hobday, R. Graham, T. Halfdanarson, 2020 .

Predictive Biomarkers and Personalized Medicine Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials , N 0234 / 336 / 436 / 437

E. Perez, A. Dueck, D. Northfelt, 2011 .

Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)

Bingshu E. Chen, T. Whelan, K. Gelmon, 2022, Cancer Research.

N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)

E. Perez, S. Nair, T. Hobday, 2005 .

A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance)

C. Loprinzi, S. Dakhil, T. Hobday, 2020, Supportive Care in Cancer.

An overview of approaches to adjuvant therapy for colorectal cancer in the United States.

T. Hobday, 2005, Clinical colorectal cancer.

Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study.

E. Mittra, E. Krenning, T. Hobday, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221)

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, G. Hortobagyi, 2018, Breast Cancer Research.

TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).

A. D. Van den Abbeele, E. Winer, R. Gelman, 2010, Journal of Clinical Oncology.

177Lu-dotatate use in chronic kidney disease patients: A single center experience

T. Hobday, G. Johnson, S. Manohar, 2021, Journal of Onco-Nephrology.

Pancreatic neuroendocrine tumors: A population-based analysis of epidemiology and outcomes.

T. Hobday, T. Halfdanarson, G. Westin, 2017 .

Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET).

Helen X. Chen, C. Erlichman, T. Hobday, 2015 .

Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer

G. Hortobagyi, C. Isaacs, W. Barlow, 2023, JAMA network open.

Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer

E. Perez, D. Northfelt, T. Hobday, 2014, American journal of clinical oncology.

Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival

G. Gores, W. Kremers, S. Sanderson, 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Risk factors for sporadic pancreatic neuroendocrine tumors (PNETs): Updated results from a single-center case control study.

W. Bamlet, G. Petersen, R. McWilliams, 2012 .

Efficacy of first‐line checkpoint inhibitors in combination with chemotherapy in high‐grade extrapulmonary metastatic neuroendocrine carcinomas

T. Hobday, T. Halfdanarson, K. Leventakos, 2023, Journal of neuroendocrinology.

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer

Minetta C. Liu, C. Isaacs, M. Goetz, 2023, JAMA oncology.

Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE : The NETTER-1 phase III trial

E. Krenning, T. Hobday, P. Ruszniewski, 2017 .

Intratumoral Interleukin-2 Injections Without Systemic Therapy for Isolated Cutaneous Metastatic Breast Cancer.

T. Hobday, J. Brewer, J. Jakub, 2021, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden

T. Hobday, G. Johnson, T. Halfdanarson, 2023, The Journal of Nuclear Medicine.